Cargando…
Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis
OBJECTIVE: To investigate β‐amyloid and tau depositions using Pittsburgh compound B (PiB) positron emission tomography (PET) and AV1451 tau PET imaging in aging multiple sclerosis (MS) patients. METHODS: Patients with MS (n = 16) and controls (n = 80) matched for age, sex, and APOE ε4 status from th...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078013/ https://www.ncbi.nlm.nih.gov/pubmed/31970802 http://dx.doi.org/10.1002/ana.25684 |
_version_ | 1783507537794957312 |
---|---|
author | Zeydan, Burcu Lowe, Val J. Reichard, Ross R. Przybelski, Scott A. Lesnick, Timothy G. Schwarz, Christopher G. Senjem, Matthew L. Gunter, Jeffrey L. Parisi, Joseph E. Machulda, Mary M. Vemuri, Prashanthi Mielke, Michelle M. Knopman, David S. Petersen, Ronald C. Jack, Clifford R. Kantarci, Orhun H. Kantarci, Kejal |
author_facet | Zeydan, Burcu Lowe, Val J. Reichard, Ross R. Przybelski, Scott A. Lesnick, Timothy G. Schwarz, Christopher G. Senjem, Matthew L. Gunter, Jeffrey L. Parisi, Joseph E. Machulda, Mary M. Vemuri, Prashanthi Mielke, Michelle M. Knopman, David S. Petersen, Ronald C. Jack, Clifford R. Kantarci, Orhun H. Kantarci, Kejal |
author_sort | Zeydan, Burcu |
collection | PubMed |
description | OBJECTIVE: To investigate β‐amyloid and tau depositions using Pittsburgh compound B (PiB) positron emission tomography (PET) and AV1451 tau PET imaging in aging multiple sclerosis (MS) patients. METHODS: Patients with MS (n = 16) and controls (n = 80) matched for age, sex, and APOE ε4 status from the population‐based Mayo Clinic Study of Aging who underwent PiB PET imaging were studied. Of these individuals, 12 patients with MS and 60 matching controls also underwent AV1451 tau PET. Cortical PiB and AV1451 standard uptake value ratios (SUVrs) from the entire cortex and previously determined Alzheimer disease (AD) signature regions in the same population were calculated for group comparisons and testing for associations with age. RESULTS: AD signature PiB SUVr (odds ratio [OR] [95% confidence interval (CI)] = 0.52 [0.27–0.98], p = 0.044), total cortical PiB SUVr (OR [95% CI] = 0.52 [0.28–0.99], p = 0.048), and the frequency of abnormal PiB SUVrs (OR [95% CI] = 0.10 [0.01–0.90], p = 0.040) were lower in MS than controls. Although AD‐signature and total cortical AV1451 SUVrs were not different between the groups, the frequency of abnormal AV1451 SUVrs was higher (OR [95% CI] = 10.65 [1.10–103.35], p = 0.041) in MS than controls. The association of AD signature PiB SUVr with age was steeper in the controls compared to patients with MS (estimate [95% CI] = −0.14 [−0.023 to −0.006], p = 0.002). Similarly, the association of total cortical PiB SUVr with age was steeper in the controls compared to patients with MS (estimate [95% CI] = −0.13 [−0.021 to −0.005], p = 0.002). There was no difference in the association of AV1451 SUVr findings with age between the MS patients and controls. INTERPRETATION: Although both β‐amyloid and tau are biomarkers of cognitive aging and AD, cortical β‐amyloid deposition was lower in MS than age‐matched controls, suggesting that some aspect of MS pathobiology retards the accumulation of β‐amyloid but not the accumulation of tau. ANN NEUROL 2020;87:556–567 |
format | Online Article Text |
id | pubmed-7078013 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70780132020-04-15 Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis Zeydan, Burcu Lowe, Val J. Reichard, Ross R. Przybelski, Scott A. Lesnick, Timothy G. Schwarz, Christopher G. Senjem, Matthew L. Gunter, Jeffrey L. Parisi, Joseph E. Machulda, Mary M. Vemuri, Prashanthi Mielke, Michelle M. Knopman, David S. Petersen, Ronald C. Jack, Clifford R. Kantarci, Orhun H. Kantarci, Kejal Ann Neurol Research Articles OBJECTIVE: To investigate β‐amyloid and tau depositions using Pittsburgh compound B (PiB) positron emission tomography (PET) and AV1451 tau PET imaging in aging multiple sclerosis (MS) patients. METHODS: Patients with MS (n = 16) and controls (n = 80) matched for age, sex, and APOE ε4 status from the population‐based Mayo Clinic Study of Aging who underwent PiB PET imaging were studied. Of these individuals, 12 patients with MS and 60 matching controls also underwent AV1451 tau PET. Cortical PiB and AV1451 standard uptake value ratios (SUVrs) from the entire cortex and previously determined Alzheimer disease (AD) signature regions in the same population were calculated for group comparisons and testing for associations with age. RESULTS: AD signature PiB SUVr (odds ratio [OR] [95% confidence interval (CI)] = 0.52 [0.27–0.98], p = 0.044), total cortical PiB SUVr (OR [95% CI] = 0.52 [0.28–0.99], p = 0.048), and the frequency of abnormal PiB SUVrs (OR [95% CI] = 0.10 [0.01–0.90], p = 0.040) were lower in MS than controls. Although AD‐signature and total cortical AV1451 SUVrs were not different between the groups, the frequency of abnormal AV1451 SUVrs was higher (OR [95% CI] = 10.65 [1.10–103.35], p = 0.041) in MS than controls. The association of AD signature PiB SUVr with age was steeper in the controls compared to patients with MS (estimate [95% CI] = −0.14 [−0.023 to −0.006], p = 0.002). Similarly, the association of total cortical PiB SUVr with age was steeper in the controls compared to patients with MS (estimate [95% CI] = −0.13 [−0.021 to −0.005], p = 0.002). There was no difference in the association of AV1451 SUVr findings with age between the MS patients and controls. INTERPRETATION: Although both β‐amyloid and tau are biomarkers of cognitive aging and AD, cortical β‐amyloid deposition was lower in MS than age‐matched controls, suggesting that some aspect of MS pathobiology retards the accumulation of β‐amyloid but not the accumulation of tau. ANN NEUROL 2020;87:556–567 John Wiley & Sons, Inc. 2020-02-08 2020-04 /pmc/articles/PMC7078013/ /pubmed/31970802 http://dx.doi.org/10.1002/ana.25684 Text en © 2020 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Articles Zeydan, Burcu Lowe, Val J. Reichard, Ross R. Przybelski, Scott A. Lesnick, Timothy G. Schwarz, Christopher G. Senjem, Matthew L. Gunter, Jeffrey L. Parisi, Joseph E. Machulda, Mary M. Vemuri, Prashanthi Mielke, Michelle M. Knopman, David S. Petersen, Ronald C. Jack, Clifford R. Kantarci, Orhun H. Kantarci, Kejal Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis |
title | Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis |
title_full | Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis |
title_fullStr | Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis |
title_full_unstemmed | Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis |
title_short | Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis |
title_sort | imaging biomarkers of alzheimer disease in multiple sclerosis |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078013/ https://www.ncbi.nlm.nih.gov/pubmed/31970802 http://dx.doi.org/10.1002/ana.25684 |
work_keys_str_mv | AT zeydanburcu imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT lowevalj imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT reichardrossr imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT przybelskiscotta imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT lesnicktimothyg imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT schwarzchristopherg imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT senjemmatthewl imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT gunterjeffreyl imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT parisijosephe imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT machuldamarym imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT vemuriprashanthi imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT mielkemichellem imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT knopmandavids imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT petersenronaldc imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT jackcliffordr imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT kantarciorhunh imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis AT kantarcikejal imagingbiomarkersofalzheimerdiseaseinmultiplesclerosis |